NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
5.36
Dollar change
-0.21
Percentage change
-3.77
%
IndexRUT P/E- EPS (ttm)-1.89 Insider Own19.25% Shs Outstand56.43M Perf Week-4.46%
Market Cap302.49M Forward P/E- EPS next Y-2.33 Insider Trans0.00% Shs Float45.57M Perf Month8.28%
Enterprise Value107.81M PEG- EPS next Q-0.59 Inst Own87.01% Short Float6.90% Perf Quarter-5.96%
Income-108.04M P/S- EPS this Y-37.06% Inst Trans4.53% Short Ratio6.26 Perf Half Y-43.82%
Sales0.00M P/B1.56 EPS next Y-0.97% ROA-31.35% Short Interest3.14M Perf YTD-40.04%
Book/sh3.44 P/C1.03 EPS next 5Y-11.81% ROE-32.89% 52W High12.92 -58.51% Perf Year-40.38%
Cash/sh5.23 P/FCF- EPS past 3/5Y59.12% 34.65% ROIC-36.88% 52W Low3.56 50.77% Perf 3Y74.03%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.25% 7.58% Perf 5Y-87.91%
Dividend TTM- EV/Sales- EPS Y/Y TTM18.70% Oper. Margin- ATR (14)0.40 Perf 10Y-
Dividend Ex-DateMar 29, 2005 Quick Ratio17.39 Sales Y/Y TTM- Profit Margin- RSI (14)50.10 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio17.39 EPS Q/Q-52.48% SMA20-3.95% Beta0.41 Target Price28.67
Payout- Debt/Eq0.02 Sales Q/Q- SMA508.47% Rel Volume0.46 Prev Close5.57
Employees78 LT Debt/Eq0.01 EarningsMay 13 AMC SMA200-31.30% Avg Volume502.37K Price5.36
IPOJun 25, 2015 Option/ShortYes / Yes EPS/Sales Surpr.-21.26% - Trades Volume239,444 Change-3.77%
Date Action Analyst Rating Change Price Target Change
Apr-29-25Initiated Cantor Fitzgerald Overweight $47
Jan-31-25Initiated JMP Securities Mkt Outperform $26
Jul-29-24Initiated TD Cowen Buy $35
Mar-28-23Initiated Evercore ISI Outperform $18
Jun-18-25 08:00AM
Jun-13-25 07:00AM
Jun-06-25 08:00AM
Jun-03-25 04:10PM
May-28-25 08:00AM
08:00AM Loading…
May-23-25 08:00AM
May-22-25 08:00AM
May-13-25 04:10PM
May-09-25 08:30AM
May-02-25 04:10PM
May-01-25 08:00AM
Apr-30-25 08:00AM
Apr-02-25 04:10PM
Mar-11-25 08:00AM
Mar-04-25 04:10PM
08:00AM Loading…
Feb-27-25 08:00AM
Feb-25-25 08:00AM
Feb-20-25 08:00AM
Feb-04-25 04:10PM
08:00AM
Feb-03-25 08:00AM
Jan-23-25 08:00AM
Jan-13-25 08:00AM
Jan-03-25 04:10PM
Dec-11-24 08:00AM
Dec-10-24 08:00AM
Dec-03-24 04:10PM
Nov-13-24 04:10PM
08:00AM
Nov-04-24 04:10PM
08:00AM Loading…
Oct-30-24 08:00AM
Oct-21-24 08:00AM
Oct-17-24 08:16AM
Oct-16-24 08:00AM
Oct-02-24 04:10PM
Sep-30-24 08:00AM
Sep-27-24 08:00AM
Sep-19-24 08:00AM
Sep-04-24 04:10PM
Aug-30-24 08:00AM
Aug-29-24 08:00AM
Aug-12-24 04:10PM
04:00PM
Aug-07-24 08:00AM
Aug-02-24 04:10PM
Jul-02-24 04:10PM
Jun-04-24 04:10PM
May-30-24 08:00AM
May-24-24 08:00AM
May-23-24 08:00AM
May-09-24 04:10PM
May-08-24 08:00AM
May-02-24 04:00PM
Apr-09-24 08:00AM
Apr-03-24 07:00PM
04:10PM
Mar-25-24 07:30AM
Mar-05-24 04:10PM
Mar-04-24 10:52PM
04:10PM
Feb-29-24 03:02AM
Feb-20-24 08:00AM
Feb-06-24 08:00AM
Feb-05-24 04:00PM
Jan-30-24 07:29PM
09:08AM
Dec-04-23 04:00PM
Nov-27-23 08:00AM
Nov-21-23 08:00AM
Nov-14-23 01:07PM
Nov-13-23 11:07AM
08:00AM
Nov-10-23 08:00AM
Nov-09-23 08:00AM
Nov-03-23 08:10AM
Nov-02-23 04:00PM
Oct-30-23 08:00AM
Oct-11-23 07:14PM
05:10PM
Oct-03-23 04:00PM
Sep-06-23 08:00AM
Aug-31-23 08:00AM
Aug-30-23 10:01AM
Aug-25-23 08:00AM
Aug-07-23 04:10PM
Aug-02-23 04:00PM
Jul-20-23 08:00AM
Jul-17-23 08:00AM
Jul-14-23 08:00AM
Jul-06-23 04:00PM
Jun-06-23 08:00AM
Jun-05-23 08:00AM
May-31-23 08:00AM
May-11-23 04:10PM
May-02-23 04:00PM
Apr-28-23 08:00AM
Apr-19-23 08:00AM
Apr-04-23 04:00PM
Mar-22-23 08:00AM
Mar-08-23 08:00AM
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.